Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive he...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical journal of the American Society of Nephrology 2020-12, Vol.15 (12), p.1728-1739
Hauptverfasser:	Muanda, Flory T, Weir, Matthew A, Bathini, Lavanya, Clemens, Kristin K, Perkovic, Vlado, Sood, Manish M, McArthur, Eric, Sontrop, Jessica M, Kim, Richard B, Garg, Amit X
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Blood Glucose - drug effects Blood Glucose - metabolism Databases, Factual Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Female Glomerular Filtration Rate Heart Failure - diagnosis Heart Failure - epidemiology Heart Failure - mortality Heart Failure - therapy Hospitalization Humans Kidney - physiopathology Male Ontario - epidemiology Original Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - mortality Risk Assessment Risk Factors Sitagliptin Phosphate - administration & dosage Sitagliptin Phosphate - adverse effects Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!